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Microbubble‑mediated delivery of human
adenoviruses does not elicit innate and adaptive
immunity response in an immunocompetent
mouse model of prostate cancer
Flavia De Carlo1,2,3, Litty Thomas1,2,3, Bell Brooke1,2,3, Elliot T. Varney4, Rounak Nande5, Olivia Boskovic5,
Gailen D. Marshall6, Pier Paolo Claudio1,2,3,7* and Candace M. Howard4*

Abstract
Background: Gene transfer to malignant sites using human adenoviruses (hAds) has been limited because of their
immunogenic nature and host specificity. Murine cells often lack some of the receptors needed for hAds attachment,
thus murine cells are generally non-permissive for human adenoviral infection and replication, which limits translational studies.
Methods: We have developed a gene transfer method that uses a combination of lipid-encapsulated perfluorocarbon microbubbles and ultrasound to protect and deliver hAds to a target tissue, bypassing the requirement of
specific receptors.
Results: In an in vitro model, we showed that murine TRAMP-C2 and human DU145 prostate cancer cells display a
comparable expression pattern of receptors involved in hAds adhesion and internalization. We also demonstrated
that murine and human cells showed a dose-dependent increase in the percentage of cells transduced by hAd-GFP
(green fluorescent protein) after 24 h and that GFP transgene was efficiently expressed at 48 and 72 h post-transduction. To assess if our image-guided delivery system could effectively protect the hAds from the immune system
in vivo, we injected healthy immunocompetent mice (C57BL/6) or mice bearing a syngeneic prostate tumor (TRAMPC2) with hAd-GFP/MB complexes. Notably, we did not observe activation of innate (TNF-α and IL-6 cytokines), or
adaptive immune response (neutralizing antibodies, INF-γ+ CD8+ T cells).
Conclusions: This study brings us a step closer to demonstrating the feasibility of murine cancer models to investigate the clinical translation of image guided site-specific adenoviral gene therapy mediated by ultrasound-targeted
microbubble destruction.
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Background
Human adenoviruses (hAds) are highly effective gene
transfer agents that can introduce different types of
genetic materials into cancer cells, including tumor
suppressor genes [1]. Taxonomically grouped into the
Adenoviridae family, adenoviruses are known to infect a
wide variety of species [2]. Human adenoviruses are nonenveloped, icosahedral viruses, approximately 90 nm in
diameter with a fiber complex known as knob domain
that binds to the Coxsackie and Adenovirus Receptor
(CAR), thus mediating cell tropism [3–5]. Interaction of
adenoviral penton proteins with surface integrins such as
αVβ3 and αVβ5 assists in the internalization of the virus;
however, horizontal gene transfer of adenoviruses is often
difficult due to the strict host specificity demonstrated by
the viruses [6]. Generally, murine cells lack some of the
receptors needed for hAd infection, such as CAR, thus
making them generally non-permissive for hAd infection
and replication. However, a very low level of hAd infection and replication has been described in some mouse
cells [7, 8].
Human adenoviruses serotypes 2 and 5, classified under
species type C, have shown promising results in treating locally advanced cancers, but these adenoviruses are
highly immunogenic triggering both innate and adaptive
immune responses [3, 4]. The innate immune response is
elicited in the professional antigen presenting cells (APC)
by hAds through the myeloid differentiating factor 88
(MyD88)/Toll-like receptor (TLR)-9 dependent or independent pathways resulting in the up-regulation of type
I interferons (IFNs) and inflammatory cytokines such
as TNF-α, IL-6 and IL-12 [9, 10]. Complement, another
key component of the innate immunity, has an important
role in the opsonization and clearance of adenoviruses.
Complement activation can occur via direct binding of
adenovirus with C3-derived fragments or through neutralizing antibodies produced after a previous immunization [11]. Viral exposure leads to innate and adaptive
immune system interaction resulting in the differentiation of B cells into antibody-secreting plasma cells and
the differentiation of T cells to cytotoxic T lymphocytes
(CTLs). Anti-adenovirus 5 serotype antibodies have been
found to target several components of the capsid, including hexons and fiber knobs, after both vaccination and
natural infection to mediate virus neutralization [2, 12].
Specifically, the humoral response causes a reduction in
the viral load hampering the systemic re-administration
of adenovirus in protocols of gene therapy [11]. While
neutralizing antibodies (NAbs) prevent re-administration
of the vector, the antigen-specific T cell response, mediated by CTLs, limits the duration of transgene expression
and eliminates transduced cells. Therefore, the success
of long-term gene therapy is dependent on the ability to
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avoid the induction of immune responses against both
vector and the transgene product [13].
When adenoviruses are directly administrated via the
circulatory system, 85–98% of the viral dose is accumulated in the liver within 30 min, and the remaining is
found in lung, kidney, and spleen resulting in off-target
interactions and systemic toxicity [2, 14]. Moreover, CAR
is present in most human cell types that contribute to offtarget transduction or non-specific interactions [2, 6].
In humans, in the absence of pre-exiting immunity
(rare in humans for Ad5 based vectors), the virus may
bind blood clotting factors [15], IgM [16] and/or erythrocytes [17]. All this leads to rapid active RES (Kupffer cell)
mediated capture and rapid clearance from the blood
[18]. The sinusoidal endothelial spaces in the human
liver measure 105 nm [19] i.e. smaller than the diameter
of a virus with intact fibre domains, providing minimal
hepatocyte access and infection, hence the minimal liver
toxicity seen in the clinics compared to mice [20]. This
is not recapitulated in mice as they do not have CAR on
their erythrocytes and have a liver sinusoidal endothelial
gap size of 130–160 nm depending on strain. Hence, RES
capture but also very high levels of liver infection and
toxicity are seen in mice.
In humans with pre-existing immunity neutralization
and RES capture may be even more effective. Unfortunately, this is not recapitulated in research mice because
they do not have pre-existing immunity, therefore in
our studies we tried to circumvent this by injecting the
mice two times with the hAds to simulate pre-existing
immunity.
The aforementioned limitations have restricted the
use of hAds for gene therapy to direct intratumoral (IT)
or organ injection [21]. To overcome these limitations,
we developed a systemic site-specific delivery system
where ultrasound (US) contrast agents, here referred as
microbubbles (MBs), are used as delivery vehicles. These
hAds, loaded inside shells of acoustically active, lyophilized, lipid-encapsulated, perfluorocarbon filled MBs, are
released when MBs are destroyed by US at the tumor site.
These bubbles range between 2.5 and 4.5 µm, and after
injection into the bloodstream, they can re-circulate
through the vascular system numerous times for several
minutes with minimal accumulation and interaction [21–
23]. Their small dimension prevents entrapment within
the pulmonary capillary bed (~ 5 to 8 µm), yet still enable proper protection of the viral vectors, such as hAds,
from the environment [21]. MBs protect the viral payload from detection and rapid degradation by the hosts’
immune system allowing for an intravenous (IV) inoculation rather than intratumoral (IT) injection [21, 24]. US
breaks open the MB/hAds complexes by inducing cavitation, allowing the hAds to transfer their transgene to the
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sonoporated region. Cavitation of the MBs causes small
shockwaves, which increase cell permeability by forming temporary micropores on the cell surface, bypassing the receptor-mediated dependence of hAds cellular
transduction.
In the recent past, we have successfully utilized this
MB gene transfer system to selectively transfer both
expression markers and therapeutic genes into tumors
in immune deficient mice [21, 25–27]. In this study, we
compared the transduction efficiency of hAd-GFP and
GFP expression in the mouse prostate cancer cell line
(TRAMP-C2, C57BL/6 background) and the human
DU145 prostate cancer cell line. Additionally, using
healthy immunocompetent C57BL/6 mice or mice bearing a syngeneic TRAMP-C2 prostate tumor, we evaluated
the capability of ultrasound contrast agents to protect
systemically-delivered adenoviral vectors from the innate
and adaptive immune system using an in vivo model,
and the contrast agent’s ability to prevent off-target distribution utilizing ultrasound-targeted microbubble
destruction.

Materials and methods
Cell lines

The DU145 (human prostate adenocarcinoma, radioresistant, p53 deficient, derived from a brain metastasis),
TRAMP-C2 (prostate adenocarcinoma, radio-resistant, wild-type p53, derived from 32-week old TRAMP
mice) and human kidney embryonic HEK-293 cell lines
were obtained from the American Type Culture Collection (ATCC, Rockville, MD). DU145 cells were grown in
RPMI-1640 (Hyclone, Waltham, MA) supplemented with
10% fetal bovine serum (FBS) (Hyclone), and 100-units/
ml penicillin supplemented with 1 mg/ml streptomycin
(Hyclone). TRAMP-C2 cells were grown in Dulbecco’s
modified Eagle’s medium (Hyclone) supplemented with
5% FBS (Hyclone), 5% Nu-Serum IV (Corning, Corning, NY), 5 μg/ml bovine insulin (Sigma Aldrich, St.
Louis, MO), 10 nM dehydroisoandrosterone 90% (Sigma
Aldrich), and 100 units/ml penicillin supplemented with
1 mg/ml streptomycin (Hyclone). The HEK-293 cells
were grown in Dulbecco’s modified Eagle’s medium
(Hyclone) supplemented with 10% FBS (Hyclone). All
cells were grown at 37 °C, in a 5% CO2 in 95% atmosphere incubator.
Adenoviral production

Human adenovirus serotype 5 E1/E3 deleted, which
expresses the GFP gene under the strong cytomegalovirus (CMV) constitutive promoter, was generated using
the Ad Easy system (Agilent Technologies, Carlsbad,
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CA) then amplified and purified with the BD Adeno-X
virus purification kit (BD Biosciences, Mountain View,
CA) following manufacturer’s directions. Viral titers
were determined by Tissue Culture Infectious Dose 50
(TCID50) and the titer was adjusted to 1 × 1011 plaqueforming units (PFU)/ml as described. Each viral stock
was propagated and purified from infected HEK-293
cells, as previously published [21, 25, 27–29]. HEK-293
cells were harvested 48 h after infection, pelleted and
suspended in medium. Cells were lysed by a three-freeze/
thaw cycle method and cell debris were removed by centrifugation. Viruses were purified by chromatography followed by dialysis and stored at − 80 °C.
Human adenovirus attachment receptors analysis

DU145 and TRAMP-C2 cells were analyzed for the
expression of hAd attachment receptors: CAR (coxsackie
adenovirus receptor), αVβ5 and αVβ3 integrins. Single
cells suspension was obtained and cells were labeled
with the following antibodies in cold FACS buffer (PBS
1× + EDTA 2 mM + FBS 0.5%): Rabbit anti-human CAR
Monoclonal antibody FITC-conjugated (10799-R271-F,
Sino Biologicals Inc, Beijing, China), Rabbit Anti-Integrin αV + β5 Polyclonal Antibody Alexa F
 luor® 647 Conjugated (bs-1356R-A647, Bioss, Woburn, MA) and Rabbit
Anti-Integrin αV + β3 (CD51 + CD61) Polyclonal Antibody Alexa F
luor® 488 Conjugated (bs-1310R-A488,
Bioss). Rabbit Isotype control antibodies were used for
background normalization. Cells were incubated for
30 min at 4 °C in the dark, then washed twice in FACS
buffer. Cells were stained with 2 µg/ml of propidium
iodide for dead cell exclusion. Samples were acquired
with a BD Accuri C6 Flow Cytometer (BD Biosciences,
San Jose, CA) and data analyzed by the CFlow Plus Analysis Software (BD Biosciences).
Transduction efficiency

Adenoviral transduction efficiency was evaluated 24 h
post-infection of mouse TRAMP-C2 and human DU145
cell lines with 10, 25, 50 MOI of hAd-GFP, using DMEM
media or RPMI-1640 media with 2% heat-inactivated FBS
(Hyclone), respectively. A qualitative analysis of the transduction efficiency was performed acquiring images of hAdGFP infected cells by fluorescence microscopy using an
inverted Olympus IX70 microscope (Olympus America,
Inc. Melville, NY). Cells were counterstained with Hoechst
33342 (Molecular Probes, Eugene, OR). Additionally, the
percentage of cells positive to GFP was measured 24-h postinfection of mouse TRAMP-C2 and human DU145 cell
lines with 10, 25, 50 MOI of hAd-GFP by flow cytometry.
Propidium iodide labeling was used to exclude dead cells.
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GFP gene expression

Transgene expression was assessed in TRAMP-C2 and
human DU145 cell lines at 24, 48, and 72 h after infection with 10 MOI of hAds, using DMEM or RPMI-1640
media with 2% heat-inactivated FBS (Hyclone), respectively. GFP median fluorescence intensity was measured
by flow cytometry. Propidium iodide staining was used to
exclude dead cells.
Preparation of microbubbles

Targeson, (Targeson, Inc. San Diego, CA) uniquely-constructed ultrasound contrast agents (perfluorocarbon
microbubbles, encapsulated by a lipid monolayer and
polyethylene glycol stabilizer), were prepared following
manufacturer’s instructions. MBs were reconstituted in
the presence or absence of 1 ml of 1 × 1011 plaque-forming units/ml of Ads and unenclosed, surface-associated
Ads were inactivated, as previously described [21, 25, 27].
Briefly, unenclosed and free adenoviruses were inactivated by incubating 1 volume of microbubbles formed
in the presence of Ad-GFP with 10 volumes of a solution containing 60 mg/ml of human complement (Sigma
Aldrich, Saint Louis, MS) for 30 min at 37 °C. Microbubbles were then washed with 10 ml of phosphate buffer
saline solution (PBS). The milky white suspension floating on the top of PBS was then collected and used in the
in vitro and in vivo experiments. We delivered 109 PFU
Ad-GFP/mouse using the MBs/US system, and the titer
was comparable to the one injected in the control mice
(IV and IT injections) (see Additional file 1).
In vivo ultrasound‑targeted microbubble destruction

Animal studies were performed in accordance with
National Institutes of Health recommendations and the
approval of the Institutional Animal Care and Use Committee. Animal care and humane use and treatment
of mice were in strict compliance with (i) institutional
guidelines, (ii) the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, Washington, DC, 1996), and (iii) the Association for Assessment
and Accreditation of Laboratory Animal Care International (Rockville, MD, 1997). All the animals used in
these studies were 8–11 week-old male C57BL/6 (H2b)
immunocompetent mice (Jackson Laboratories, Bar
Harbor, ME). Two in vivo experiments were performed
using a total of 30 mice divided into groups containing
3–6 mice for each experiment. The first experiment was
performed in healthy C57BL/6 mice while the second utilized C57BL/6 bearing a syngeneic TRAMP-C2 tumor. To
establish syngeneic tumor grafts, the mice were injected
in the right flank with TRAMP-C2 prostate adenocarcinoma cell lines (5 × 106 cancer cells) using a 20-gauge
needle. Treatment was started when the tumor reached
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50–100 mm3 of volume. During the experimental procedure, the mice were sedated using an IMPAQ6 anesthesia apparatus (VetEquip, Pleasanton, CA) saturated with
3–5% isofluorane and 10–15% oxygen with the aid of a
precision vaporizer (VetEquip), and placed on a warming
mat set at 37 °C. Treatments were delivered intravenously
(IV) or intratumorally (IT) in a volume of 100 μl using
a 30-gauge needle. US exposure was performed with a
Micro-Maxx SonoSite ultrasound machine (SonoSite)
equipped with the transducer L25 set at 0.7 Mechanical
Index (MI), 1.8 MPa for 10 min [21, 25, 27].
TNF‑α and IL‑6 quantification

Two hours after the first IV or IT injection, mice were
deeply sedated and 100 μl of blood was collected by
puncture of the mandibular vein using a Goldenrod Animal Lancet (Braintree Scientific, Inc., Braintree, MA).
Mouse serum TNF-α and IL-6 levels were analyzed using
Quantikine HS Mouse TNF-alpha (R&D System, Minneapolis, MN) and Quantikine Mouse IL-6 and (R&D
System) Immunoassay solid-phase ELISAs, following
manufacturer’s directions.
Anti‑adenovirus antibodies detection

At the experimental endpoints, mice were deeply anesthetized, and blood was collected from the heart. Afterwards, the mice were sacrificed by CO2 gas and cervical
dislocation.
ELISA plates were coated overnight at 4 °C with
5 × 106 vp/well of Ad-GFP. Plates were blocked for 2 h at
room temperature with 3% BSA/PBS. Mice serum was
heat inactivated at 56 °C for 30 min, diluted 1:3000 in
1%BSA/0.05%Tween20/PBS, added to the wells in triplicate and incubated for 2 h at room temperature. Reactive antibodies were detected using a secondary antibody
sheep anti-mouse IgG HRP-conjugated (NA931, GE
Healthcare, Chicago, IL). SureBlue TMB Peroxidase Substrate (KPL, Gaithersburg, MD) was added to each well
and color development was assessed at 650 nm using a
microplate reader.
INF‑γ ELISPOT

Immediately following mice euthanasia, spleens were
collected and processed. Red blood cells were removed
using a Red Blood Cells Lysis buffer (Affymetrix, Santa
Clara, CA). Splenocytes were suspended at 2 × 106 cells/
ml in AIM V medium containing l-glutamine, streptomycin sulfate 50 µg/ml, and gentamicin sulfate 10 µg/ml,
and supplemented with 50 µM 2-mercaptoethanol. Two
hundred-thousand cells/well were stimulated with 2 µg/
ml of DNA-binding protein peptide, corresponding to
DBP418–426 (FASLNAEDL, H-2Db restricted peptide, New
England Peptide, Gardner, MA) [30] for 24 h. Stimulation
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of splenocytes with 0.05 µg/ml of anti-mouse CD3 was
used as positive control (552774, BD Biosciences, Franklin Lakes, NJ). Splenocytes were subjected to ELISpot assay using the INF-γ ELISpot PLUS kit (Mabtech,
Nacka Strand, Sweden) following manufacturer’s directions. Spots, corresponding to INF-γ secreting cells, were
counted using a Zeiss ELISpot reader system (service
provided by ZellNet, Inc. Fort Lee, NJ).
Statistical analysis

Statistical analysis was performed using GraphPad Prism
6 statistical software (Graphpad, Inc., La Jolla, CA). One
and two-way analysis of variance (ANOVA) with Tukey
or Bonferroni multiple comparisons post-test was used
to determine the statistical significance of the differences
between experimental groups. Multiple t-test was used
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for the ELISpot analysis. p-values of less than 0.05 were
considered statistically significant.

Results
TRAMP‑C2 and DU145 cells express hAd receptors
integrins αVβ5, αVβ3, and CAR

The expression profile of surface proteins known to be
responsible for the specific attachment of hAd5 to human
cells was evaluated by flow cytometry (Fig. 1a, b). Both
human DU145 and mouse TRAMP-C2 prostate cancer
cells were positive to the expression of integrin αVβ5 and
αVβ3. The percentage of cells expressing human Coxsackie and Adenovirus Receptor (CAR), as expected, was
higher in the human cell line DU145 when compared to
the mouse TRAMP C2 cells (97 ± 0.9% vs. 62.9 ± 1.5%).

Fig. 1 Human adenoviral receptors expression in TRAMP-C2 and DU145. a TRAMP-C2 and DU145 cells were labeled with Rabbit Anti-human
Coxsackie adenovirus receptor FITC conjugated (hCAR), Rabbit Anti-Integrin αV + β5 Alexa F luor® 647 Conjugated and Rabbit Anti-Integrin αV + β3
Alexa Fluor® 488 Conjugated. Percentages are represented as mean ± SEM of three biological repetitions. b Representative flow cytometer
histograms showing the percentage of cells that are expressing human adenovirus receptors. Black: negative control, Red: isotype control, Blue:
specific antibody
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TRAMP‑C2 and DU145 cells are transduced by hAd‑GFP

Despite the high host specificity of adenovirus, we
wanted to define if murine cells could be infected by a
hAd. The transduction efficiency of murine TRAMP-C2
and human DU145 prostate cancer cell lines by hAdGFP was assessed 24 h post infection with 10, 25, and
50 MOI (multiplicity of infection) of hAd-GFP. Using
fluorescence microscopy, we observed a dose-dependent
increase of GFP positive cells in both TRAMP-C2 and
DU145 cells (Fig. 2a). DU145 cells exhibited a higher level
of transduction in comparison to TRAMP-C2 cells at
each multiplicity of infection.
To quantify TRAMP-C2 and DU145 cells transduction with hAd-GFP at 10, 25, and 50 MOI, a flow cytometry analysis was performed 24 h post infection (Fig. 2b).
An increase in the percentage of GFP positive cells was
observed in both TRAMP-C2 and DU145 cells as the
MOI was increased. However, when comparing similar
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treatments, TRAMP-C2 cells were significantly less
affected than were DU145 as indicated by a GFP positive
population of only 17.7 ± 2.8% at 50 MOI in TRAMP-C2
vs 59 ± 1.5% in DU145.
TRAMP‑C2 and DU145 cells express GFP
following transduction with hAd‑GFP

The hAds-GFP used in this study express the GFP gene
under the strong (CMV) cytomegalovirus constitutive
promoter. In order to assess if mouse TRAMP-C2 and
human DU145 prostate cancer cells were able to express
GFP after transduction with hAd-GFP, both cell lines
were infected with 10 MOI of hAds, and the median
fluorescence intensity (MFI) was measured at 24, 48, and
72 h to determine the degree of GFP protein synthesis.
We showed that the GFP transgene is expressed in both
TRAMP-C2 (Fig. 3a) and DU145 (Fig. 3b) cell lines.
When comparing human and murine cell lines, GFP

Fig. 2 Human adenoviral transduction efficiency in TRAMP-C2 and DU145. a TRAMP-C2 and DU145 cells were transduced with 10, 25, 50 MOI of
hAd-GFP for 24 h and images were acquired by fluorescence microscopy. Nuclei were counterstained with Hoechst 3334. b TRAMP-C2 and DU145
cells were transduced with 10, 25, 50 MOI of hAd-GFP for 24 h and the percentage of cells transduced were determined by flow cytometry. Data are
representative of three biological repeats, analyzed by two way ANOVA, Bonferroni’s post-test ***p < 0.001
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MFI in DU145 was higher than TRAMP-C2 at all 3 times
points corresponding to a greater transduction efficiency
of hAds in human cells. However, when GFP MFI was
corrected by the percentage of GFP+ cells detected at 24,
48 and 72 h, a similar GFP expression in both murine and
human cells was observed (Fig. 3c).
Microbubbles protect hAd‑GFP from activation
of the innate immune system

The first barrier to viral infection is the innate immunity,
which is comprised of cellular and soluble components
including complement, immunoglobulin, erythrocyte
and clotting factor binding (depending on species), and
inflammatory cytokines (TNF-α, IL-1β, IL-6) [13]. To
evaluate the MBs’ ability to protect in immune competent
animals the hAds from the innate immunity, the levels of
serum inflammatory cytokines after IV and IT injection
of both unprotected hAd-GFP and MB-protected hAdGFP were measured using immunoassay solid-phase
ELISAs. The experimental design is shown in Fig. 4.
Direct IV injection of unprotected hAd-GFP in healthy
C57BL/6 immunocompetent mice (Fig. 4a, EXP.1)
induces a marked increase in both TNF-α (Fig. 5a) and
IL-6 (Fig. 5b) in comparison to control groups (saline
and MBs only). As anticipated, the administration of
MB-protected hAd-GFP completely shielded the adenovirus, preventing the activation of innate immunity in
both ultrasound-treated and non-treated groups. When
C57BL/6 mice bearing a syngeneic tumor were used
(Fig. 4b, EXP.2), we detected an increase in both TNF-α
(Fig. 5c) and IL-6 (Fig. 5d) in hAd-GFP IV injected mice
just as we did using C57BL/6 mice without tumor; however, the increase in IL-6 using hAd-GFP IV injected mice
was less substantial than that of the C57BL/6 mice without tumor. When C57BL/6 mice bearing tumors received
an IT injection, the level of TNF-α was again comparable to the hAd-GFP IV group, but IL-6 production was
absent. As expected, we observed that the administration
of hAd-GFP/MBs complexes allows for the evasion of
adenovirus from the innate immunity with or without the
use of ultrasound.
Microbubbles protect hAd‑GFP from the activation
of the humoral response

The production of neutralizing antibodies specific for
hAd-GFP (IgG anti-hAd) was evaluated using a direct
ELISA assay. Blood was collected from the heart at the
experimental endpoints of 2 months in C57BL/6 mice
(Fig. 4a, EXP.1) and 1 month in C57BL/6 mice bearing a syngeneic tumor (Fig. 4b, EXP.2). There was a statistically higher titer of IgG anti-hAd when mice were
injected intravenously with unprotected hAd-GFP. The
production levels of neutralizing antibodies specific for

Fig. 3 GFP protein expression in TRAMP-C2 and DU145. a TRAMP-C2
and b DU145 cells were transduced with 10 MOI of hAd-GFP and the
median fluoresce intensity of GFP transgene (GFP MFI) was analyzed
by flow cytometry at 24, 48 and 72 h post transduction. c GFP MFI
was corrected by the percentage of GFP positive (GFP+) cells to
compare GFP expression in equal number of transduced cells. Data
are representative of three biological repeats analyzed by (a, b)
one way ANOVA, Tukey’s post-test +p<0.05, ++p < 0.01; c two ways
ANOVA, Bonferroni’s post-test, *p < 0.05, **p < 0.01

hAd-GFP nearly doubled when mice received two IV
injections of unprotected hAd-GFP in EXP.1 (Fig. 6a).
C57BL/6 mice from EXP.2 (Fig. 6b) that received an IT
injection of hAd-GFP showed a lower increase in NAbs
when compared to the IV injection groups. Not surprisingly, we observed that the administration of MBs/
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Fig. 4 In vivo experimental design. Two in vivo experiments were performed. a In experiment 1 we used healthy C57BL/6. Mice were injected IV
with either saline, MBs, hAd-GFP, MBs(hAd-GFP), or MBs(hAd-GFP) + US. Blood samples were collected 2 h post-injection to determine inflammatory
cytokine response. After 4 weeks, mice were re-injected and 4 weeks later, mice were sacrificed and blood and organs were collected. b In
experiment 2 we used C57BL/6 mice injected subcutaneously with 5 × 106 TRAMP-C2 cells. When syngeneic tumor grafts were established
(approximately 3 weeks post-injection of cancer cells, and with tumor volumes between 50 and 100 mm3) mice were injected IV with either
saline, MBs, hAd-GFP, MBs(hAd-GFP), MBs(hAd-GFP) + US, or via IT with hAd-GFP. Two hours after the treatment, blood samples were collected to
determine inflammatory cytokine response. At the endpoint of 4 weeks, mice were sacrificed and blood and organs were collected. Activation of
the innate and adaptive immune response were evaluated in both experiments by ELISA (TNF-α, IL-6 and NAbs)

hAd-GFP complexes ± US completely prevented the
activation of a humoral response in immune competent
mice.
Microbubbles protect hAd‑GFP from the activation
of the cellular response

The presence of antigen-specific INF-γ producing C
 D8+
T cells was assessed by stimulating the splenocytes
ex vivo with D
 BP418–426 peptide. The number of cells
responding to the stimulation was evaluated using an
ELISpot assay. Splenocytes were collected at the experimental endpoints. A statistically higher amount of INF-γ
spot forming units were found in the stimulated splenocytes compared to the un-stimulated splenocytes in the

IV-injected, unprotected hAd-GFP mice. The number of
INF-γ spot forming units counted in samples from mice
in EXP.1 (Fig. 7a, c) that received two IV injections of
unprotected hAd-GFP was almost twofold of that which
was observed in the mice from EXP.2 (Fig. 7b, d). Mice
from EXP.2 (Fig. 7b) that received an IT injection of
hAd-GFP showed a greater number of INF-γ spot forming units when compared to the IV injections. Notably,
we did not observe a statistically significant activation
of splenocytes after stimulation with DBP418–426 in mice
that received MBs/hAd-GFP complexes ± US treatment
indicating that the UMTD we developed prevented the
activation of a humoral response in immune competent
mice.
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Fig. 5 Quantification of serum inflammatory cytokines. Innate immunity was evaluated by sandwich ELISA by quantifying serum cytokines TNF
alpha a EXP.1, and c EXP.2, and serum IL-6 b EXP.1, and d EXP.2. Groups means are represented as horizontal bars (EXP.1 n = 6 mice/group; XPp.2
n = 4 mice for saline IV, MBs IV, hAd-GFP IV, MBs(hAd-GFP) IV groups and n = 3 mice for MBs(hAd-GFP) + US IV and hAd-GFP IT. Data are analyzed by
two way ANOVA and Tukey’s post-test, *p < 0.05, ***p < 0.001)

Discussion
Prostate cancer is a very common cancer in men in the
United States ranking as the third-leading cause of cancer death in men [31]. Primary prostate cancer can be
treated successfully in many cases with surgical prostate
resection, radiation, and hormonal therapy, with radiation therapy being used as the main choice for locally
advanced prostate cancer. However despite receiving
treatment, over a third of these patients will progress
to an androgen-independent, radiation-resistant prostate cancer [32]. There is a need to develop more effective therapeutic approaches, and gene therapy represents
a promising new treatment option. Therapeutic genes
of choice include pro-apoptotic genes, tumor suppressor genes, antisense sequences for oncogenes, and antitumor DNA vaccines. Recent gene therapy clinical trials
for prostate cancer have used Adenovirus as a highly

efficient gene transducing tool [24]. Together with the
Adeno-associated virus, adenoviral vectors belong to the
category of the non-integrating vectors, they can be produced at a higher titer and display a robust expression of
the therapeutic genes. These vectors can be easily engineered to make them safer and less immunogenic [33].
For example, the substitution of serotype 5 hexons with
serotype 3 can protect adenovirus form inactivation by
neutralizing antibody anti-hAd5 that are commonly circulating in patients due to preexisting immunization [34,
35]. In fact, the main challenges associated with the systemic delivery of adenoviral vector are not only the naïve
immune response but also the immunity to the virus
serotype stemming from natural infection and liver toxicity [13].
Adenoviruses interact with the host cell and internalize
using specific receptors. Adenovirus 5 is one of the main
serotypes currently used in the clinics, and it employs
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Fig. 6 Detection of serum neutralizing antibodies. Humoral response was determined by direct ELISA of serum NAbs (IgG anti-hAd), a Exp.1, b
Exp.2. Group’s means are represented as horizontal bars. (EXP.1 n = 6 mice/group; EXP.2 n = 4 mice for saline IV, MBs IV, hAd-GFP IV, MBs (hAd-GFP) IV
groups and n = 3 mice for MBs(hAd-GFP) + US IV and hAd-GFP IT. Data are analyzed by two way ANOVA and Tukey’s post-test, *p < 0.05, **p < 0.01,
***p < 0.001)

Fig. 7 Detection of INF-γ producing CD8+ T. Cellular response was assay by ELIspot counting the number of INF-γ spots forming units after ex vivo
stimulation of splenocytes with DBP418–426 peptide a, c EXP.1, b, d EXP.2. Group means are represented as in the histograms. c, d Exemplary samples.
The nonspecific activator anti-CD3 antibody was used as positive control for the assay. (EXP.1 and EXP.2 n = 3 mice/group. Data are analyzed by
multiple t-test of splenocytes from control and treated mice stimulated with media, spontaneous, or D
 BP418–426, stimulated, *p < 0.05, ***p < 0.001)

Coxsackie and Adenovirus Receptor (CAR) to adhere to
target cells [36]. This receptor is expressed at low levels
in primary tumors, including prostate cancer, when compared to established human cancer cell lines [37].
Infection and replication by human adenovirus has
been thought to be restricted to human cells. Murine
cells have been generally considered non-permissive,

thereby limiting preclinical studies of gene transfer techniques [38]. However, here we showed that murine tissue
could be transduced with hAds even if at a lower extent.
To overcome the aforementioned challenges through
elicitation of the immune response and off-target viral
distribution and expression, we have developed an imageguided gene transfer method (US Patent 8,454,937)
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utilizing a combination of lipid-encapsulated perfluorocarbon microbubbles (MBs) and ultrasonic waves (US)
to enclose and protect hAds from the immune system to
deliver the adenoviruses to a site-specific tissue bypassing the requirement of specific receptors [21, 25–27].
We have previously shown in immune compromised
mice that this innovative gene transfer system can be
used to specifically deliver hAd-GFP to a prostate tumor
xenograft after systemic injection of the virus [25]. We
demonstrated, by delivering a replication-deficient or a
conditionally replication-competent adenovirus expressing the pro-apoptotic gene mda7/interleukin-24 enclosed
in microbubble and in combination with ultrasound, that
we could achieve sustained expression of the transgene in
the sonoporated region and induce a reduction or complete eradication of a human prostate tumor xenograft
[21]. Using this microbubble gene transfer method we
were also able to radio-sensitize and reduce the tumor
burden of a tumor xenograft of the prostate cell line
DU145 by delivering replication-deficient human adenovirus expressing the tumor suppressor genes p53, and
pRb [27]. Moreover, we confirmed our previously published data, showing that after reconstitution of microbubbles in the presence of adenovirus, the microbubbles
need to be treated with human complement in order to
inactivate any adenovirus loosely attached or included
within the lipid shell and to achieve specific delivery of
the hAds. The complement-treated microbubble-encapsulated adenovirus can be systemically injected intravenously into an immunocompetent C57BL/6 mouse
without eliciting any innate immune response when
compared to non-treated microbubbles or not protected
adenovirus [24, 25].
The validity of our established image-guided gene
therapy method has been confirmed by an independent
laboratory that is using ultrasound-targeted microbubble (MB)-destruction to deliver conditionally replicationcompetent oncolytic adenoviruses that simultaneously
produce a systemically active cancer-specific therapeutic
cytokine [39] in prostate cancer.
The aim of the present study was to test if the microbubble/US system we have established [21, 24, 25, 27]
could efficiently deliver human adenoviruses to a targeted
diseased tissue protecting the virus from the innate and
adaptive immunity using immunocompetent TRAMPC2 mice (C57BL/6 background) as pre-clinical prostate
cancer model.
Using an in vitro model, we compared the transduction efficiency of the hAd-GFP in the mouse TRAMP-C2
and human DU145 prostate cancer cell lines and found
that the pattern of expression of the CAR receptors and
integrins αVβ5 and αVβ3, all required for the adhesion
and internalization of the adenovirus by the host cells,
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was comparable. However, notwithstanding this similarity, we observed a pronounced reduction in the uptake of
the virus when comparing murine cells and human prostate cell line. This can be explained by the high sequence
homology in the extracellular domain of CAR from
human and mice [40, 41] and CAR-independent pathways for cell transduction [42]. However, we detected a
dose-dependent increase of the GFP positive cells in both
cell lines 24 h post-infection. Finally, and more relevant
for the general purpose of our study, we showed that both
mouse TRAMP-C2 and human DU145 prostate cancer
cell lines were able to support an efficient expression of
the GFP transgene regulated by the strong CMV promoter at 48 and 72 h post-transfection.
The second goal of this study was to test the ability of
the microbubbles to protect the systemically delivered
adenoviral vectors from the innate and adaptive immune
system of an immunocompetent mouse in vivo, using our
image-guided delivery system. For this purpose, we used
the TRAMP-C2 model of prostate cancer. From the original TRAMP mouse, that spontaneously develops prostate cancer, several cell lines have been established, such
as TRAMP-C1 and C2, and these can be used to establish
syngeneic subcutaneous grafts in C57BL/6 mice [43]. In
our study, we used healthy immunocompetent C57BL/6
mice and mice bearing a syngeneic TRAMP-C2 prostate
tumor to better represent the immune response of cancer
patients.
Adenoviruses are able to induce a strong inflammatory
response, which at its first step involves the activation of
NK, professional APC, neutrophils, the complement cascade and the secretion of cytokines [13]. Dendritic cells in
the spleen have been demonstrated to be directly transduced by systemically administered adenovirus resulting in the induction of IL-6, IL-12, and other cytokines
[44]. The administration of human adenoviral vectors
in protocols of gene therapy can lead to side effects in
patients such as liver toxicity, thrombocytopenia and
acute inflammation [45]. In order to assess if the microbubbles could protect the hAds from the activation of the
innate immunity following systemic delivery, we injected
the hAds enclosed in microbubbles through the tail vein
of the mice. Two hours after intravenous injection, corresponding to the previously reported median time of
secretion peak for TNF-α and IL-6 in C57BL/6 mice [46–
48], blood samples were collected from the treated mice
and levels of cytokines in their serum were quantified.
We observed that the microbubbles completely protected
hAds from eliciting an immune response, as showed
by the absence of inflammatory cytokines when compared to the expected and well-documented response
obtained after injection of non-protected hAds [11, 13,
44, 49, 50]. We did not observe any difference among
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ultrasound-treated and non-treated mice (EXP.1 to the
right kidney, EXP.2 to the tumor on the right flank), confirming the high stability of the microbubbles used. Furthermore, we noticed a very low level or absence of virus
leak when bubbles cavitation was induced by sonoporation. Mice that received an intratumoral injection of
the hAds showed an increase of only TNF-α expression,
which naturally precedes IL-6 [46, 48], suggesting that
anatomical barriers such as the tight junction between
tumor cells may have reduced the path of the viral vector
delaying the elicitation of innate immunity.
The second barrier to viral infection is the adaptive
immunity, which is comprised of activated C
 D4+, CD8+
T cells and antibody-secreting plasma cells [13]. During
a scheduled treatment of cancer gene therapy, the real
obstacle to effectively repeating systemic administrations of replication-deficient adenoviral vectors is the
inactivation of the virus by complement proteins, preexisting anti-viral and neutralizing antibodies that can
reduce the efficiency of transfection [11, 13]. In order
to assess the activation of the adaptive immunity, at the
experimental end point of 1 month from the last injection of microbubble encapsulated hAds either in combination with US or not, we measured the levels of serum
IgG anti-adenovirus. We observed that the microbubbles
completely protected hAds injected intravenously from
eliciting a humoral response as shown by the absence
of a statistically significant increase in secretion of antihAds antibodies. We could not detect differences among
mice that received ultrasound treatment or not, confirming once again our previous observations. On the other
hand, we detected a robust production of neutralizing
antibodies in mice injected intravenously with unprotected hAds as observed by others [11, 13]. Additionally,
in mice injected intravenously with unprotected hAds,
the relative number of neutralizing antibodies detected
was twice as much in EXP.1 compared to EXP.2 due to
the treatment schedule. Instead, intratumoral injection of
hAds induced a lower titer of neutralizing antibody probably due to the target tissue characteristics and the route
of administration.
To assess the activation of cell-mediated immunity, we
investigated the incidence of antigen specific INF-γ producing CD8+ T cells. The vector we used in our experiments is a 1st generation, E1 deleted adenovirus that
still allows for the leaky late gene expression of some
viral products including the nonstructural DNA Binding
Protein (DBP). DBP contains a MHC-class I restricted
epitope that have been shown to be a C
 D8+ principal
epitope in C57BL/6 mice [30]. In order to detect the presence of DBP specific INF-γ producing C
 D8+ T cells, we
performed an INF-γ ELIspot assay. We collected splenocytes at the experimental end points and stimulated them
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ex vivo with the DBP peptide and INF-γ spot forming
units were counted. We observed that the systemic injection of microbubble encapsulated hAd-GFP with or without the use of US treatment does not induce a statistically
significant increase in the number of spots observed
when compared to the spontaneous release of INF-γ in
both healthy mice (EXP.1) and mice bearing a prostate
tumor (EXP.2). Conversely, we observed a strong activation of CD8+ T cells in the positive controls (IV and IT
injections of naked hAds) and the highest count of INF-γ
spot forming units was detected after intratumoral injection of hAd-GFP confirming that the route of administration and viral dose administered may affect the type of
immune response [30, 51, 52].

Conclusions
These results demonstrated that our MBs/US-guided
gene delivery system can effectively protect a viral vector
from the activation of both humoral and cellular immunity response. Also, our data provides evidence that the
TRAMP-C2 mouse model of prostate cancer is a suitable
system to study the feasibility of this novel image-guided
gene transfer technique in immune competent animals
offering the milestone and opportunity to further translate this ultrasound-mediated MBs/hAd delivery system
from the bench to the bedside.
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dilution tested and the control (only media). Figure S2. Enhancement
of Human Adenoviral transduction efficiency in TRAMP-C2 and DU145
following US-mediated MBs(Ad) delivery system. TRAMP-C2 and DU145
cells were transduced with 10MOI of Ad-GFP or MBs(Ad-GFP)+US. Cells
receiving MBs(Ad-GFP) were treated with US for 1 minute. 24 hours after
infection, the percentage of cells transduced were determined by Flow
Cytometry. Data are representative of three biological repeats, analyzed by
Student T-test (Ad-GFP vs. MBs(Ad-GFP)+US). *p < 0.05, **p < 0.001.
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